Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 5;10:931004. doi: 10.3389/fnut.2023.931004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Wu, Yang, Cao, Wang, Wang, Chen, Wu, Zheng, Jin and Yang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of the levels of I-FABP and FC between the drug group and short-chain polypeptide-based EEN plus drug group before and after treatment. (A,C) Levels of I-FABP in children with mild active CD. (B,D) Levels of FC in children with moderate-to-severe active CD. Short peptide: short-chain polypeptide-based EEN formulas. Drug regimen in mild active CD (oral mesalazine) and drug regimen in moderate-to-severe active CD (intravenous methylprednisolone or oral prednisone). *Compared with the drug group, p < 0.05.